File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

TitlePatients with osteoporosis prefer once weekly to once daily dosing with alendronate
Authors
Issue Date2004
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitas
Citation
Maturitas, 2004, v. 48 n. 3, p. 243-251 How to Cite?
AbstractObjectives: Once weekly dosing of alendronate has been shown to provide equivalent efficacy to once daily dosing for treatment of osteoporosis in postmenopausal women. Whether patients will prefer weekly dosing to daily dosing for a chronic condition such as osteoporosis has not been studied. The aim of this international study was to assess preference for the weekly or daily dosing regimen of alendronate among postmenopausal women with osteoporosis. Methods: This randomised open-label crossover study was conducted at 45 study sites in 19 countries. Four hundred and six postmenopausal women with osteoporosis were assigned randomly to treatment with either alendronate 70 mg once weekly for 4 weeks followed by alendronate 10 mg once daily for 4 weeks or vice versa. The main outcome was the responses of the participants to the Dosing Regimen Questionnaire administered at the end of the study. Results: Of the participants expressing a preference, 84% preferred the once weekly dosing regimen with alendronate to the once daily dosing regimen. In addition, the once weekly regimen was considered by 87% of the participants to be more convenient and was the regimen most of the participants (84%) would be more willing to take for a long period of time (P<0.001 for each parameter). Conclusions: The majority of postmenopausal women with osteoporosis preferred the once weekly to the once daily dosing regimen of alendronate. Physicians should consider patient preference for dosing regimen when selecting the appropriate treatment for osteoporosis. © 2004 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163562
ISSN
2015 Impact Factor: 3.12
2015 SCImago Journal Rankings: 1.107
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKendler, Den_US
dc.contributor.authorKung, AWCen_US
dc.contributor.authorFuleihan, GEHen_US
dc.contributor.authorGonzález González, JGen_US
dc.contributor.authorGaines, KAen_US
dc.contributor.authorVerbruggen, Nen_US
dc.contributor.authorMelton, MEen_US
dc.date.accessioned2012-09-05T05:37:25Z-
dc.date.available2012-09-05T05:37:25Z-
dc.date.issued2004en_US
dc.identifier.citationMaturitas, 2004, v. 48 n. 3, p. 243-251en_US
dc.identifier.issn0378-5122en_US
dc.identifier.urihttp://hdl.handle.net/10722/163562-
dc.description.abstractObjectives: Once weekly dosing of alendronate has been shown to provide equivalent efficacy to once daily dosing for treatment of osteoporosis in postmenopausal women. Whether patients will prefer weekly dosing to daily dosing for a chronic condition such as osteoporosis has not been studied. The aim of this international study was to assess preference for the weekly or daily dosing regimen of alendronate among postmenopausal women with osteoporosis. Methods: This randomised open-label crossover study was conducted at 45 study sites in 19 countries. Four hundred and six postmenopausal women with osteoporosis were assigned randomly to treatment with either alendronate 70 mg once weekly for 4 weeks followed by alendronate 10 mg once daily for 4 weeks or vice versa. The main outcome was the responses of the participants to the Dosing Regimen Questionnaire administered at the end of the study. Results: Of the participants expressing a preference, 84% preferred the once weekly dosing regimen with alendronate to the once daily dosing regimen. In addition, the once weekly regimen was considered by 87% of the participants to be more convenient and was the regimen most of the participants (84%) would be more willing to take for a long period of time (P<0.001 for each parameter). Conclusions: The majority of postmenopausal women with osteoporosis preferred the once weekly to the once daily dosing regimen of alendronate. Physicians should consider patient preference for dosing regimen when selecting the appropriate treatment for osteoporosis. © 2004 Elsevier Ireland Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitasen_US
dc.relation.ispartofMaturitasen_US
dc.rightsMaturitas. Copyright © Elsevier Ireland Ltd.-
dc.subject.meshAgeden_US
dc.subject.meshAlendronate - Administration & Dosageen_US
dc.subject.meshCross-Over Studiesen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOsteoporosis, Postmenopausal - Drug Therapy - Psychologyen_US
dc.subject.meshPatient Satisfactionen_US
dc.subject.meshQuestionnairesen_US
dc.titlePatients with osteoporosis prefer once weekly to once daily dosing with alendronateen_US
dc.typeConference_Paperen_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.maturitas.2003.12.012en_US
dc.identifier.pmid15207890-
dc.identifier.scopuseid_2-s2.0-2942659309en_US
dc.identifier.hkuros91393-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-2942659309&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume48en_US
dc.identifier.issue3en_US
dc.identifier.spage243en_US
dc.identifier.epage251en_US
dc.identifier.isiWOS:000222567800008-
dc.publisher.placeIrelanden_US
dc.identifier.scopusauthoridKendler, D=23970860600en_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US
dc.identifier.scopusauthoridFuleihan, GEH=8377894400en_US
dc.identifier.scopusauthoridGonzález González, JG=55112960400en_US
dc.identifier.scopusauthoridGaines, KA=7003859635en_US
dc.identifier.scopusauthoridVerbruggen, N=6603790538en_US
dc.identifier.scopusauthoridMelton, ME=7003559912en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats